DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin

Oct 01, 2007, 01:00 ET from DAIICHI SANKYO EUROPE GmbH

    MUNICH, Germany, October 1 /PRNewswire/ --
     - New Product Under Development for the Treatment of High Blood
     - Approval Requested in 28 European Countries
     DAIICHI SANKYO EUROPE GmbH has applied in 28 European countries for
 approval of a new antihypertensive medication. It is a fixed combination
 (CS-8663) of two substances, the angiotensin receptor blocker (ARB)
 Olmesartan and the calcium antagonist Amlodipin.
     When approved, the new combination for treatment of essential
 hypertension is designed for use in patients whose blood pressure cannot be
 adequately controlled through therapy with the respective monopreparation.
 In clinical trials the combination of Olmesartan / Amlodipin (CS-8663) has
 shown a significant lowering of blood pressure. In the new fixed
 combination, two complementary therapeutic approaches are combined:
 blocking of the angiotensin II receptor and blocking of the calcium
 channel. Olmesartan is already being marketed by DAIICHI SANKYO and is the
 angiotensin receptor blocker with the greatest sales growth in Europe(1).
 Amlodipin is one of the most frequently used calcium antagonists in many
 European countries.
     "Hypertension is currently viewed as the number one cause of death.
 Most patients need two or even more medications to normalise their blood
 pressure. The new fixed combination has proved to be effective and well
 tolerated in a large number of patients. That also applies to patients who
 have very high blood pressure at the start of therapy," says Dr Petra
 Laeis, Head of Clinical Research at DAIICHI SANKYO EUROPE. "The combination
 of the two well-known agents Olmesartan and Amlodipin in one tablet gives
 doctors another effective treatment option for hypertension, which can lead
 to better results because patients are more likely to use it faithfully,"
 continues Dr Laeis.
     DAIICHI SANKYO is a worldwide, research-oriented pharmaceutical
 company, created through the merger of the two traditional Japanese
 enterprises Daiichi and Sankyo. The company is one of the world's leading
 manufacturers of medication. The company's research activities focus on the
 areas of cardiovascular, haematology, diabetes, anti-infectives and cancer.
 DAIICHI SANKYO has its European headquarters in Munich.
     For additional information, please visit our website at
     (1) Source: IMS MIDAS Juli 2007
     Dr Andrea Jager
     Vice Director Operative Marketing
     Telephone +49-(0)89-78-08-454